次世代乳がん診断とスクリーニング市場- 世界の産業規模、シェア、動向、機会、予測、技術別、バイオマーカー別、がんサブタイプ別、提供サービス別、エンドユーザー別、地域別、競合別セグメント、2020-2030F

次世代乳がん診断とスクリーニングの世界市場は、2024年に46億5,000万米ドルと評価され、予測期間には85億3,000万米ドルに達し、2030年までのCAGRは10.61％に達すると予測されています。

次世代乳がん診断とスクリーニング法は、乳がんを検出・診断するための先進的かつ革新的なアプローチを指します。これらの方法は、乳がんの検出、診断、リスク評価の精度と有効性を向上させるために、最先端技術、分子的洞察、個別化アプローチを組み込んだものです。次世代法は、特定の遺伝子マーカーに基づく乳がんの分子サブタイピングを可能にします。このサブタイプ分類は、腫瘍の挙動に関する洞察を提供し、最も適切な治療戦略の決定に役立ちます。一般的なサブタイプには、ホルモン受容体陽性乳がん、HER2陽性乳がん、トリプルネガティブ乳がんなどがあります。世界の乳がん罹患率の増加は重要な原動力となっています。乳がんの罹患率が上昇を続ける中、乳がんを早期に発見するための高度な診断法やスクリーニング法の需要も高まっています。

乳房画像診断、遺伝子検査、分子診断における継続的な技術進歩により、乳がんの精度と早期発見が向上し、これらの技術に対する需要が高まっています。個別化医療へのシフトにより、患者の乳がんサブタイプや遺伝子プロファイルに関する個別化された情報を提供する診断検査への需要が高まっています。この情報は治療決定の指針となります。乳がん啓発キャンペーンや早期発見を促進する取り組みにより、より多くの女性が定期的に乳がん検診を受けるようになり、市場の成長に寄与しています。

主な市場促進要因

技術の進歩

主な市場課題

倫理的・法的問題

主な市場動向

マルチオミックスデータの統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の次世代乳がん診断とスクリーニング市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 技術別（リアルタイムPCR、免疫組織化学（IHC）、次世代シークエンシング（NGS）、蛍光in-situハイブリダイゼーション（FISH）、その他）
  • バイオマーカー別（BRCA1/2、ER/PR受容体、HER-2、その他）
  • がんのサブタイプ別（ルミナルA、ルミナルB、トリプルネガティブ/基底細胞様、ヒト上皮成長因子受容体2（HER-2）濃縮）
  • 提供内容（製品、サービス）
  • エンドユーザー別（病院、診療所、診断センター、リファレンスラボ、学術調査機関）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の次世代乳がん診断とスクリーニング市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の次世代乳がん診断とスクリーニング市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の次世代乳がん診断とスクリーニング市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の次世代乳がん診断とスクリーニング市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの次世代乳がん診断とスクリーニング市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の次世代乳がん診断とスクリーニング市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Abbott Laboratories
• Agendia Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• BGI Genomics Co., Ltd.
• CENTOGENE N.V.
• Danaher Corporation
• Exact Sciences Corporation
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Lucence Diagnostics Pte Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Next-Generation Breast Cancer Diagnostic and Screening Market was valued at USD 4.65 Billion in 2024 and is expected to reach USD 8.53 Billion in the forecast period with a CAGR of 10.61% through 2030. Next-generation breast cancer diagnostic and screening methods refer to advanced and innovative approaches to detecting and diagnosing breast cancer. These methods incorporate cutting-edge technologies, molecular insights, and personalized approaches to improve the accuracy and effectiveness of breast cancer detection, diagnosis, and risk assessment. Next-generation methods enable the molecular subtyping of breast cancer based on specific genetic markers. This subtyping provides insights into the tumor's behavior and helps determine the most appropriate treatment strategy. Common subtypes include hormone receptor-positive, HER2-positive, and triple-negative breast cancer. The increasing incidence of breast cancer worldwide has been a significant driver. As breast cancer rates continue to rise, the demand for advanced diagnostic and screening methods to detect the disease at an early stage has also increased.

Ongoing technological advancements in breast imaging, genetic testing, and molecular diagnostics have improved the accuracy and early detection of breast cancer, driving demand for these technologies. The shift toward personalized medicine has led to an increased demand for diagnostic tests that provide individualized information about a patient's breast cancer subtype and genetic profile. This information guides treatment decisions. Breast cancer awareness campaigns and initiatives promoting early detection have encouraged more women to undergo regular breast cancer screening, contributing to market growth.

Key Market Drivers

Advancements in Technology

Digital mammography has largely supplanted traditional film mammography, offering enhanced image quality, streamlined storage and retrieval, and the capability to manipulate images for improved visualization of breast tissue. As of June 2023, the U.S. Food and Drug Administration reported that 87% of mammography facilities in the United States have adopted 3D mammography systems, also known as breast tomosynthesis, which capture multiple X-ray images from different angles to create a three-dimensional representation of the breast. This technology has been shown to reduce false positives and improve cancer detection, particularly in women with dense breast tissue.

Breast Magnetic Resonance Imaging (MRI) utilizes powerful magnets and radio waves to generate detailed images of breast tissue, proving especially useful for assessing disease extent and detecting tumors in high-risk women. Advanced ultrasound technologies, including elastography and contrast-enhanced ultrasound, offer additional insights into breast lesions, aiding in distinguishing between benign and malignant tumors. Genetic testing has advanced with next-generation sequencing, allowing simultaneous analysis of multiple genes to comprehensively assess mutations associated with breast cancer.

Key Market Challenges

Ethical and Legal Issues

As next-generation diagnostic and screening methods generate large volumes of sensitive patient data, ensuring privacy and data security becomes paramount. Ethical concerns arise regarding the storage, sharing, and protection of patient genetic and medical information. Patients must provide informed consent before undergoing genetic testing or other screening procedures. Ensuring that patients fully understand the implications of the tests, including potential psychological and medical consequences, is an ethical imperative. Concerns about genetic discrimination in employment, insurance, and other areas may deter individuals from undergoing genetic testing. Legal protections against such discrimination are essential to address these concerns. Ethical and legal questions arise about who owns the genetic and medical data generated through screening. This includes issues related to data access, sharing, and commercialization. Next-generation screening technologies must adhere to regulatory standards to ensure safety, accuracy, and efficacy. Navigating the complex regulatory landscape can be a challenge for companies and healthcare providers. Ethical issues related to healthcare equity and access arise when next-generation screening technologies are not equally available to all populations. Disparities in access can lead to unequal health outcomes.

Key Market Trends

Integration of Multi-Omics Data

Multi-omics approaches enable healthcare providers to obtain a detailed profile of breast cancer at the molecular level. This includes information on genetic mutations, gene expression patterns, protein activity, metabolite levels, and epigenetic modifications. Integration of multi-omics data allows for precise molecular subtyping of breast cancer, which helps tailor treatment strategies based on the unique characteristics of each patient's tumor. This approach enhances the effectiveness of targeted therapies and minimizes unnecessary treatments. Multi-omics data analysis can identify biomarkers associated with early-stage breast cancer and risk prediction. This aids in early detection and risk assessment, enabling healthcare providers to intervene at an earlier, more treatable stage. Multi-omics analysis identifies specific molecular targets within breast cancer cells that can be exploited for treatment. This leads to the development of targeted therapies and more effective treatment options. Multi-omics data can be used to monitor a patient's response to treatment over time. Changes in gene expression, protein activity, or metabolite levels can indicate treatment efficacy or the need for therapeutic adjustments.

Key Market Players

• Abbott Laboratories
• Agendia Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Genomics Co., Ltd.
• CENTOGENE N.V
• Danaher Corporation
• Exact Sciences Corporation
• Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Lucence Diagnostics Pte Ltd.

Report Scope:

In this report, the Global Next-Generation Breast Cancer Diagnostic and Screening Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next-Generation Breast Cancer Diagnostic and Screening Market, By Technology:

• Real-Time PCR
• Immunohistochemistry (IHC)
• Next-Generation Sequencing (NGS)
• Fluorescence In-Situ Hybridization (FISH)
• Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Biomarker:

• BRCA1/2
• ER/PR Receptors
• HER-2
• Others

Next-Generation Breast Cancer Diagnostic and Screening Market, By Cancer Sub-Type:

• Luminal A
• Luminal B
• Triple Negative/Basal Like
• Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched

Next-Generation Breast Cancer Diagnostic and Screening Market, By Offering:

• Products
• Services

Next-Generation Breast Cancer Diagnostic and Screening Market, By End User:

• Hospitals and Clinics
• Diagnostic Centers, and Reference Labs
• Academic and Research Institutes

Next-Generation Breast Cancer Diagnostic and Screening Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next-Generation Breast Cancer Diagnostic and Screening Market.

Available Customizations:

Global Next-Generation Breast Cancer Diagnostic and Screening Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Real-Time PCR, Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescence In-Situ Hybridization (FISH), Others)
  • 5.2.2. By Biomarker (BRCA1/2, ER/PR Receptors, HER-2, Others)
  • 5.2.3. By Cancer Sub-Type (Luminal A, Luminal B, Triple Negative/Basal Like, Human Epidermal Growth Factor Receptor 2 (HER-2) Enriched)
  • 5.2.4. By Offering (Products, Services)
  • 5.2.5. By End User (Hospitals and Clinics, Diagnostic Centers, and Reference Labs, Academic and Research Institutes)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Biomarker
  • 6.2.3. By Cancer Sub-Type
  • 6.2.4. By Offering
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Biomarker
      • 6.3.1.2.3. By Cancer Sub-Type
      • 6.3.1.2.4. By Offering
      • 6.3.1.2.5. By End User
  • 6.3.2. India Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Biomarker
      • 6.3.2.2.3. By Cancer Sub-Type
      • 6.3.2.2.4. By Offering
      • 6.3.2.2.5. By End User
  • 6.3.3. Australia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Biomarker
      • 6.3.3.2.3. By Cancer Sub-Type
      • 6.3.3.2.4. By Offering
      • 6.3.3.2.5. By End User
  • 6.3.4. Japan Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Technology
      • 6.3.4.2.2. By Biomarker
      • 6.3.4.2.3. By Cancer Sub-Type
      • 6.3.4.2.4. By Offering
      • 6.3.4.2.5. By End User
  • 6.3.5. South Korea Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Technology
      • 6.3.5.2.2. By Biomarker
      • 6.3.5.2.3. By Cancer Sub-Type
      • 6.3.5.2.4. By Offering
      • 6.3.5.2.5. By End User

7. Europe Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Biomarker
  • 7.2.3. By Cancer Sub-Type
  • 7.2.4. By Offering
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Biomarker
      • 7.3.1.2.3. By Cancer Sub-Type
      • 7.3.1.2.4. By Offering
      • 7.3.1.2.5. By End User
  • 7.3.2. Germany Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Biomarker
      • 7.3.2.2.3. By Cancer Sub-Type
      • 7.3.2.2.4. By Offering
      • 7.3.2.2.5. By End User
  • 7.3.3. Spain Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Biomarker
      • 7.3.3.2.3. By Cancer Sub-Type
      • 7.3.3.2.4. By Offering
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Biomarker
      • 7.3.4.2.3. By Cancer Sub-Type
      • 7.3.4.2.4. By Offering
      • 7.3.4.2.5. By End User
  • 7.3.5. United Kingdom Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Biomarker
      • 7.3.5.2.3. By Cancer Sub-Type
      • 7.3.5.2.4. By Offering
      • 7.3.5.2.5. By End User

8. North America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Biomarker
  • 8.2.3. By Cancer Sub-Type
  • 8.2.4. By Offering
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Biomarker
      • 8.3.1.2.3. By Cancer Sub-Type
      • 8.3.1.2.4. By Offering
      • 8.3.1.2.5. By End User
  • 8.3.2. Mexico Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Biomarker
      • 8.3.2.2.3. By Cancer Sub-Type
      • 8.3.2.2.4. By Offering
      • 8.3.2.2.5. By End User
  • 8.3.3. Canada Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Biomarker
      • 8.3.3.2.3. By Cancer Sub-Type
      • 8.3.3.2.4. By Offering
      • 8.3.3.2.5. By End User

9. South America Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Biomarker
  • 9.2.3. By Cancer Sub-Type
  • 9.2.4. By Offering
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Biomarker
      • 9.3.1.2.3. By Cancer Sub-Type
      • 9.3.1.2.4. By Offering
      • 9.3.1.2.5. By End User
  • 9.3.2. Argentina Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Biomarker
      • 9.3.2.2.3. By Cancer Sub-Type
      • 9.3.2.2.4. By Offering
      • 9.3.2.2.5. By End User
  • 9.3.3. Colombia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Biomarker
      • 9.3.3.2.3. By Cancer Sub-Type
      • 9.3.3.2.4. By Offering
      • 9.3.3.2.5. By End User

10. Middle East and Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Biomarker
  • 10.2.3. By Cancer Sub-Type
  • 10.2.4. By Offering
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Biomarker
      • 10.3.1.2.3. By Cancer Sub-Type
      • 10.3.1.2.4. By Offering
      • 10.3.1.2.5. By End User
  • 10.3.2. Saudi Arabia Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Biomarker
      • 10.3.2.2.3. By Cancer Sub-Type
      • 10.3.2.2.4. By Offering
      • 10.3.2.2.5. By End User
  • 10.3.3. UAE Next-Generation Breast Cancer Diagnostic and Screening Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Biomarker
      • 10.3.3.2.3. By Cancer Sub-Type
      • 10.3.3.2.4. By Offering
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Next-Generation Breast Cancer Diagnostic and Screening Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Abbott Laboratories
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Agendia Inc.
• 16.3. Agilent Technologies, Inc.
• 16.4. Bio-Rad Laboratories, Inc.
• 16.5. BGI Genomics Co., Ltd.
• 16.6. CENTOGENE N.V.
• 16.7. Danaher Corporation
• 16.8. Exact Sciences Corporation
• 16.9. F. Hoffmann-La Roche Ltd.
• 16.10. Illumina, Inc.
• 16.11. Thermo Fisher Scientific Inc.
• 16.12. Lucence Diagnostics Pte Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer